XRTX Stock Overview
A late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XORTX Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.22 |
| 52 Week High | CA$7.00 |
| 52 Week Low | CA$1.09 |
| Beta | -0.21 |
| 11 Month Change | -21.29% |
| 3 Month Change | 0.82% |
| 1 Year Change | -58.22% |
| 33 Year Change | -94.26% |
| 5 Year Change | -93.19% |
| Change since IPO | -91.94% |
Recent News & Updates
Shareholder Returns
| XRTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.3% | 1.6% | 2.2% |
| 1Y | -58.2% | 9.9% | 31.6% |
Return vs Industry: XRTX underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: XRTX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| XRTX volatility | |
|---|---|
| XRTX Average Weekly Movement | 41.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XRTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XRTX's weekly volatility has increased from 26% to 41% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Allen Davidoff | www.xortx.com |
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
XORTX Therapeutics Inc. Fundamentals Summary
| XRTX fundamental statistics | |
|---|---|
| Market cap | US$3.99m |
| Earnings (TTM) | -US$736.66k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs XRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$736.66k |
| Earnings | -US$736.66k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XRTX perform over the long term?
See historical performance and comparison